Startup Glycomine raises $115M to push rare disease drug deeper into testing
The biotech is developing an experimental drug for the most common of a family of disorders all caused by errors in glycosylation.
The biotech is developing an experimental drug for the most common of a family of disorders all caused by errors in glycosylation.
